Deals, Legal

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta

BioMarin $BMRN may have lost big on their expensive and high-profile bid to get an OK for a troubled Duchenne muscular dystrophy drug, but the West Coast biotech is getting a consolation prize from Sarepta — the big winner so far in the US with its marketed drug Exondys 51.

Doug Ingram

Sarepta $SRPT is paying BioMarin $35 million to settle their scrap over rights to exon-skipping tech, reserving some 5% and 8% royalty streams for certain exon-skipping therapies. And new Sarepta CEO Doug Ingram lauded the fact that the biotech now has “worldwide freedom” to operate on a drug that it wholly controls.

A filing with the SEC, though, provides some details on this settlement that aren’t in the release. Sarepta states:

Under the terms of the License Agreement, the Company is required to pay BioMarin an upfront payment of $15 million, and BioMarin will be eligible to receive up to $20 million from the Company per dystrophin gene exon (other than exon 51) targeted by one or more Products in specified regulatory milestones, as well as an additional $10 million milestone, payable following the regulatory approval of eteplirsen by the European Medicines Agency. BioMarin will also be eligible to receive $15 million from the Company upon the achievement of $650 million in sales, as well as royalties segmented by specified geographic markets, in some of jurisdictions dependent on an the existence of a patent, ranging from four (4) to eight (8) digit percentages of net sales on a product-by-product and country-by-country basis.

BioMarin gambled $680 million in cash when it decided to buy Prosensa and its failed DMD drug drisapersen and make a bid to revive its prospects at the FDA. That effort was hit head on by the FDA’s rejection in early 2016. If BioMarin chooses to go for another exon-skipping drug, the company has rights to opt in on a co-exclusive deal with Sarepta.

“We are pleased to reach a global settlement and license agreement with Sarepta that fairly recognizes the important innovation by the Leiden University Medical Center and allows patients certainty that this issue will not create a barrier to access,” said BioMarin general counsel G Eric Davis.

 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->